Please use this identifier to cite or link to this item:
|Title:||P-glycoprotein and vacuolar ATPase synergistically confer anthracycline resistance to fission yeast and human cells|
|Source:||Tay, Z.,Koo, S.H.,Nguyen, T.T.T.,Tan, T.S.,Chen, M.L.,Chin, C.F.,Lim, K.K.,Ang, W.H.,Bay, B.H.,Lee, E.J.D.,Chen, E.S. (2014-01). P-glycoprotein and vacuolar ATPase synergistically confer anthracycline resistance to fission yeast and human cells. Current Medicinal Chemistry 21 (2) : 251-260. ScholarBank@NUS Repository. https://doi.org/10.2174/09298673113206660269|
|Abstract:||Drug resistance is a major hurdle to the success of chemotherapy. The permeability glycoprotein (P-gp) is an important factor dictating drug access to the cells, as it controls the efflux of chemotherapeutic agents against the concentration gradient. Pmd1, a P-gp-like protein, was recently isolated as a doxorubicin resistance gene in fission yeast. Although the null mutant of pmd1 (Δpmd1) exhibited sensitivity to doxorubicin, it showed an unexpectedly high resistance to the drug at relatively high concentrations. The data presented here suggest that this is due to the presence of cooperative processes that can complement and counteract drug cytotoxicity in the absence of Pmd1. One such factor, Rav1, is an essential factor in controlling the assembly of the pH-regulating transporter vacuolar-ATPase (V-ATPase) in fission yeast. The simultaneous disruption of Pmd1 and Rav1 resulted in a prominent accumulation of doxorubicin in the cytoplasm of cells, accompanied by a decline in cell viability. With concurrent treatment of pharmacological inhibitors in human cervical cancer cells, P-gp and V-ATPase were further shown to act synergistically to sensitize cells to doxorubicin also in the human cells. Furthermore, a novel Cornichon-like protein SPAC2C4.05 (herein named as Cor1) was demonstrated for the first time to be involved in the interaction with P-gp and V-ATPase to counteract doxorubicin-dependent cytotoxicity. Therefore this study identified a molecular cooperation between multiple membrane transporter proteins that confers chemoresistance to cells against the chemical insult of doxorubicin. Interestingly, this network exhibited differential effects to doxorubicin as compared with its close epimeric analog epirubicin, suggestive of the intricacy of the drug response regulated by this synergistic interaction. A model is discussed on how the versatility of this network can differentiate closely related chemical drug structures yet allow for the robustness to counteract a vast range of drugs. © 2014 Bentham Science Publishers.|
|Source Title:||Current Medicinal Chemistry|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Mar 6, 2018
checked on Mar 8, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.